Federico Cappuzzo

Dr. Federico Cappuzzo

Medical Oncology, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SCSerena Ceddia
Serena Ceddia
LLLorenza Landi
Lorenza Landi
Federico CappuzzoFederico Cappuzzo
Federico Cappuzzo
KRAS is the most frequently mutated oncogene identified in human cancers. Despite the numerous efforts to develop effective specific inhibitors against KRAS, this molecule has remained “undruggable” for decades. The development of direct KRAS inhibitors, such as sotorasib, the first FDA-approved drug targeting KRAS G12C, or adagrasib, was made possible with the discovery of a small pocket in the binding switch II region of KRAS G12C. However, a new challenge is represented by the necessity to overcome resistance mechanisms to KRAS inhibitors. Another area to be explored is the potential role of co-mutations in the selection of the treatment strategy, particularly in the setting of immune checkpoint inhibitors. The aim of this review was to analyze the state-of-the-art of KRAS mutations in non-small-cell lung cancer by describing the biological structure of KRAS and exploring the clinical relevance of KRAS as a prognostic and predictive biomarker. We reviewed the different treatment approaches, focusing on the novel therapeutic strategies for the treatment of KRAS-mutant lung cancers.

Verified
Journal Article
Open access
PDF file
EKEriseld Krasniqi
Eriseld Krasniqi
FGFrauke Goeman
Frauke Goeman
Claudio PulitoClaudio Pulito
Claudio Pulito
APAlina Catalina Palcau
Alina Catalina Palcau
LCLudovica Ciuffreda
Ludovica Ciuffreda
PVPatrizia Vici
Patrizia Vici
New evidence on the impact of dysregulation of the CDK4/6 pathway on breast cancer (BC) cell proliferation has led to the development of selective CDK4/6 inhibitors, which have radically changed the management of advanced BC. Despite the improved outcomes obtained by CDK4/6 inhibitors, approximately 10% of tumors show primary resistance, whereas acquired resistance appears to be an almost ubiquitous occurrence, leading to treatment failure. The identification of differentially expressed genes or genomic mutational signatures able to predict sensitivity or resistance to CDK4/6 inhibitors is critical for medical decision making and for avoiding or counteracting primary or acquired resistance against CDK4/6 inhibitors. In this review, we summarize the main mechanisms of resistance to CDK4/6 inhibitors, focusing on those associated with potentially relevant biomarkers that could predict patients’ response/resistance to treatment. Recent advances in biomarker identification are discussed, including the potential use of liquid biopsy for BC management and the role of multiple microRNAs as molecular predictors of cancer cell sensitivity and resistance to CDK4/6 inhibitors.

16 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Irene TerrenatoIrene Terrenato
Irene Terrenato
CECristiana Ercolani
Cristiana Ercolani
ABAnna Di Benedetto
Anna Di Benedetto
EGEnzo Gallo
Enzo Gallo
EMElisa Melucci
Elisa Melucci
SBSimonetta Buglioni
Simonetta Buglioni
The approval of osimertinib for adjuvant treatment of stage I–II–III EGFR-mutated NSCLC (early stage) represents a paradigm shift, raising the question of whether other genotype-matched therapeutics approved for advanced-stage NSCLC can also provide clinical benefit in the adjuvant setting. However, there is a paucity of real-world data on the prevalence of actionable genomic alterations (GAs) in early-stage NSCLC. We used next-generation sequencing, complemented by immunohistochemistry and fluorescence in situ hybridization, to screen our single-institution cohort of 1961 NSCLC consecutive cases for actionable molecular targets. The prevalence of actionable GAs was comparable in early versus advanced-stage NSCLC, the only exception being KRAS mutations (more frequent in early-stage cases). Consistent with advanced-stage tumors being more aggressive, co-occurrence of TP53 and EGFR GAs as well as copy number gains were less frequent in early-stage tumors. EGFR mutations and high expression of PD-L1 were inversely associated, whereas KRAS mutations and high PD-L1 reactivity showed positive association. Recapitulating advanced-stage tumors, early-stage NSCLC had the highest share of EGFR mutations in lepidic and acinar subtypes. Resected lepidic tumors contained the highest proportion of the KRAS G12C actionable variant. These results, obtained with routine diagnostic technologies in an unselected clinical setting, provide a significant addition of real-world data in early-stage NSCLC.

13 April 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FGFilippo Tommaso Gallina
Filippo Tommaso Gallina
RTRiccardo Tajè
Riccardo Tajè
DFDaniele Forcella
Daniele Forcella
FCFelicita Corzani
Felicita Corzani
VCVirna Cerasoli
Virna Cerasoli
Francesco FaccioloFrancesco Facciolo
Francesco Facciolo
Background: While the thoracotomy approach was considered the gold standard until two decades ago, robotic surgery has increasingly strengthened its role in lung cancer treatment, improving patients’ peri-operative outcomes. In this study, we report our experience in robotic lobectomy for early-stage non-small cell lung cancer, with particular attention to oncological outcomes and nodal upstaging rate. Methods: We retrospectively reviewed patients who underwent lobectomy and radical lymphadenectomy at our Institute between 2016 and 2020. We selected 299 patients who met the inclusion criteria of the study. We analyzed the demographic features of the groups as well as their nodal upstaging rate after pathological examination. Then, we analyzed disease-free and overall survival of the entire enrolled patient population and we compared the same oncological outcomes in the upstaging and the non-upstaging group. Results: A total of 299 patients who underwent robotic lobectomy were enrolled. After surgery, 55 patients reported nodal hilar or mediastinal upstaging. The 3-year overall survival of the entire population was 82.8%. The upstaging group and the non-upstaging group were homogeneous for age, gender, smoking habits, clinical stage, tumor site, tumor histology. The non-upstaging group had better OS (p = 0.004) and DFS (p < 0.0001). Conclusion: Our results show that robotic surgery is a safe and feasible approach for the treatment of early-stage NSCLC, especially for its accuracy in mediastinal lymphadenectomy. The oncological outcomes were encouraging and consistent with previous findings.

28 May 2024 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
ASAnna La Salvia
Anna La Salvia
MMMay-Lucie Meyer
May-Lucie Meyer
FHFred R. Hirsch
Fred R. Hirsch
KKKeith M. Kerr
Keith M. Kerr
LLLorenza Landi
Lorenza Landi
Federico CappuzzoFederico Cappuzzo
Federico Cappuzzo

13 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
FGFilippo Tommaso Gallina
Filippo Tommaso Gallina
Luca BertolacciniLuca Bertolaccini
Luca Bertolaccini
DFDaniele Forcella
Daniele Forcella
SMShehab Mohamed
Shehab Mohamed
SCSerena Ceddia
Serena Ceddia
Francesco FaccioloFrancesco Facciolo
Francesco Facciolo
Next-generation sequencing has become a cornerstone in clinical oncology practice and is recommended for the appropriate use of tailored therapies in NSCLC. While NGS has already been standardised in advanced-stage NSCLC, its use is still uncommon in the early stages. The recent approval of Osimertinib for resected EGFR-mutated NSCLC in an adjuvant setting has launched the hypothesis that other targeted therapies used in metastatic patients can also lead to improved early-stage outcomes of NSCLC. The impact of molecular biomarkers on the prognosis of patients undergoing radical surgery for NSCLC is still unclear. Notably, the heterogeneous populations included in the studies that analysed surgical patients could be the main reason for these results. In this review, we report the most important studies that analysed the impact of principal molecular biomarkers on the survival outcomes of patients who underwent radical surgery for NSCLC.